^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Gastric Cancer
    Drug:Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

    Excerpt:
    ......
    Trial ID:
    NCT07474324
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

    Excerpt:
    ...- HER2 overexpression defined as HER2 IHC 2+ or 3+....
    Trial ID:
    NCT03556345
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Exploratory Study of Disitamab Vedotin Combination Therapy in Advanced Gastrointestinal Tumors with HER2 Overexpression or Amplification

    Excerpt:
    ......
    Trial ID:
    ChiCTR2500114011
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

    Excerpt:
    ...Use pre-treatment endoscopic biopsy samples for HER2 detection in the local laboratory: HER2 high expression confirmed after IHC results (defined as: IHC 2+ 3+); 7....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

    Excerpt:
    ...- HER2 overexpression defined as HER2 IHC 2+ or 3+....
    Trial ID:
    NCT04714190
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

    Published date:
    05/19/2021
    Excerpt:
    ...9 (30%) harbored HER2 mutation/overexpression (received RC48-ADC or trastuzumab, cohort B)…In cohort B, ORR was 44% (4/9), DCR was 78% (7/9), mPFS and mOS was 3.1 months and 5.5 months, respectively.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

    Published date:
    05/13/2020
    Excerpt:
    RC48-ADC demonstrated a clinically meaningful response and survival benefit in the heavily treated patients with HER2-overexpressing gastric or gastro-esophageal junction cancers.
    DOI:
    10.1200/JCO.2020.38.15_suppl.4560
    Trial ID:
    NCT03556345